IBRX
ImmunityBio, Inc. · Healthcare · Market cap $8.8B
Insiders sold $1.1M net in the last 90 days ·2 sellers, 0 buyers· 2 of 2 sales under Rule 10b5-1 plans· latest Form 4 filed Oct 6, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$9.5M
reported sales (SEC code S)
Unique Insiders
3
in the rolling window
Latest filing
Oct 6, 2026
Simon Barry J.
ImmunityBio, Inc. (IBRX) has 23 SEC Form 4 filings (51 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: Oct 6, 2026.
Inside the rolling window, 3 insiders at ImmunityBio, Inc. reported no open-market purchases and 15 open-market sales totaling $9.5M. The most active filer is Director Simon Barry J. with 7 filings. Insiders have net sold $5.0M over the trailing 6 months. The most recent open-market filing is a sale of 25,000 shares by Director Simon Barry J., dated Oct 5, 2026, worth $269K.
- Industry:Biotechnology
- CEO:Richard Gerald Adcock
- Employees:688
- HQ:San Diego, CA, US
- IPO:2015-07-28
| Source | |||||||
|---|---|---|---|---|---|---|---|
Simon Barry J.First in 3 months | Director | Sale | 25,000 | $269K | Oct 6 | -14.4% | SEC ↗ |
Cohen CherylFirst in 3 months | Director | Sale | 81,056 | $851K | Oct 6 | -14.4% | SEC ↗ |
Cohen CherylFirst filing | Director | Sale | 131,210 | $1.2M | Jul 7 | -5.4% | SEC ↗ |
| Director | Sale | 159,478 | $1.4M | Jul 7 | -5.4% | SEC ↗ | |
Selecky ChristobelFirst in 4 months | Director | Sale | 95,722 | $862K | Jul 1 | -9.9% | SEC ↗ |
Selecky ChristobelFirst in 4 months | Director | Sale | 1,000 | $9K | Jul 1 | -9.9% | SEC ↗ |
| Director | Sale | 25,000 | $197K | Jun 27 | -5.5% | SEC ↗ | |
Simon Barry J.First in 3 months | Director | Sale | 23,033 | $165K | Jun 5 | +19.8% | SEC ↗ |
| Director | Sale | 75,000 | $901K | Feb 26 | -13.2% | SEC ↗ | |
| Director | Sale | 10,000 | $93K | Feb 24 | -28.2% | SEC ↗ | |
| Director | Sale | 165,000 | $1.7M | Feb 24 | — | SEC ↗ | |
| Director | Sale | 25,000 | $250K | Feb 24 | — | SEC ↗ | |
Selecky ChristobelFirst filing | Director | Sale | 50,000 | $250K | Jan 21 | — | SEC ↗ |
Selecky ChristobelFirst filing | Director | Sale | 25,000 | $188K | Jan 21 | — | SEC ↗ |
Simon Barry J.First filing | Director | Sale | 151,967 | $1.1M | Jan 21 | — | SEC ↗ |
Earnings: last 7 quarters
Congress trading IBRX 1 all-time
- DRep. Daniel GoldmanOther$1,001 - $15,0002023-03-06
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Frequently asked questions
How many SEC Form 4 insider filings does IBRX have?
ImmunityBio, Inc. (IBRX) has 23 SEC Form 4 filings (51 transaction rows) in the rolling 365-day window, disclosed by 3 distinct insiders. Most recent filing: Oct 6, 2026.
When was the most recent SEC Form 4 filing for IBRX?
The most recent Form 4 filing for IBRX on Tracefour is dated Oct 6, 2026.
Who is the most active insider at IBRX?
The most active SEC Form 4 filer at IBRX in the rolling window is Director Simon Barry J., with 7 filings.
What is the net insider flow at IBRX over the last 6 months?
Over the trailing 180 days, insiders at IBRX have net sold $5.0M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at IBRX in the current window?
Inside the rolling window, insiders at IBRX bought $0 and sold $9.5M based on SEC Form 4 filings.
Can I get alerts for IBRX insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at ImmunityBio, Inc. (IBRX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
ImmunityBio, Inc. is in the Healthcare sector.